Literature DB >> 22401929

The prognostic significance of chemokine receptor CXCR3 expression in colorectal carcinoma.

Zhenqian Wu1, Xiaodong Han, Jun Yan, Ye Pan, Jianfeng Gong, Jianzhong Di, Zhe Cheng, Zhiming Jin, Zhigang Wang, Qi Zheng, Yu Wang.   

Abstract

The expression of chemokine receptor CXCR3 has been associated with tumor dissemination and poor prognosis in breast cancer patients. However, it is still unclear whether CXCR3 can be used as an independent molecular marker for predicting the prognosis of colonrectal carcinoma (CRC) patients. In this study, we found that the relative level of CXCR3 mRNA expression in primary colorectal cancer tissues was significantly higher than that in corresponding non-tumor colon tissues. CXCR3 protein expression was also detected in 98 of 112 primary CRC patients. Thus, CXCR3 might play a vital role in the progression of colorectal cancer. By analyzing the correlation between clinicopathological factors of patients and expression of CXCR3 protein, we showed that high level of CXCR3 protein expression was significantly associated with tumor differentiation, tumor size, lymph node metastasis, distant metastasis, and Dukes' classification, but not with other factors of CRC patients including gender, age, tumor location and tumor invasion. Furthermore, patients with high CXCR3 expression showed poorer overall survival than those with low CXCR3 expression. Univariate and multivariate analysis indicated that the status of CXCR3 protein expression might be an independent prognostic marker for CRC patients. Therefore, CXCR3 is an indicator of a poor prognosis and a promising target for cancer therapy in colorectal cancer.
Copyright © 2012 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22401929     DOI: 10.1016/j.biopha.2011.12.003

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  15 in total

1.  CXCR3 deficiency enhances tumor progression by promoting macrophage M2 polarization in a murine breast cancer model.

Authors:  Steve Oghumu; Sanjay Varikuti; Cesar Terrazas; Dmitri Kotov; Mohd W Nasser; Catherine A Powell; Ramesh K Ganju; Abhay R Satoskar
Journal:  Immunology       Date:  2014-09       Impact factor: 7.397

2.  High expression of CXCR3 is an independent prognostic factor in glioblastoma patients that promotes an invasive phenotype.

Authors:  Yi Pu; Shouwei Li; Chuanbao Zhang; Zhaoshi Bao; Zhengxiang Yang; Lihua Sun
Journal:  J Neurooncol       Date:  2014-12-20       Impact factor: 4.130

3.  Oxaliplatin inhibits colorectal cancer progression by inhibiting CXCL11 secreted by cancer-associated fibroblasts and the CXCR3/PI3K/AKT pathway.

Authors:  Caifu Lu; Cong Zhang
Journal:  Clin Transl Oncol       Date:  2022-09-21       Impact factor: 3.340

4.  A novel prognostic model for osteosarcoma using circulating CXCL10 and FLT3LG.

Authors:  Ricardo J Flores; Aaron J Kelly; Yiting Li; Manjula Nakka; Donald A Barkauskas; Mark Krailo; Lisa L Wang; Laszlo Perlaky; Ching C Lau; M John Hicks; Tsz-Kwong Man
Journal:  Cancer       Date:  2016-08-16       Impact factor: 6.860

5.  Impact of chemokine receptor CXCR3 on tumor-infiltrating lymphocyte recruitment associated with favorable prognosis in advanced gastric cancer.

Authors:  Kai Li; Zhengpeng Zhu; Jin Luo; Jingyi Fang; Huanhuan Zhou; Min Hu; Ninu Maskey; Guifang Yang
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

6.  The expression of chemokine receptors CXCR3 and CXCR4 in predicting postoperative tumour progression in stages I-II colon cancer: a retrospective study.

Authors:  Changzheng Du; Yunfeng Yao; Weicheng Xue; Wei-Guo Zhu; Yifan Peng; Jin Gu
Journal:  BMJ Open       Date:  2014       Impact factor: 2.692

7.  CXCR3 mediates ascites-directed tumor cell migration and predicts poor outcome in ovarian cancer patients.

Authors:  C Windmüller; D Zech; S Avril; M Boxberg; T Dawidek; B Schmalfeldt; M Schmitt; M Kiechle; H Bronger
Journal:  Oncogenesis       Date:  2017-05-15       Impact factor: 7.485

8.  CXCR3 is a prognostic marker and a potential target for patients with solid tumors: a meta-analysis.

Authors:  Yang Zhang; Linjuan Xu; Minggang Peng
Journal:  Onco Targets Ther       Date:  2018-02-27       Impact factor: 4.147

Review 9.  CXC family of chemokines as prognostic or predictive biomarkers and possible drug targets in colorectal cancer.

Authors:  Sara Cabrero-de Las Heras; Eva Martínez-Balibrea
Journal:  World J Gastroenterol       Date:  2018-11-14       Impact factor: 5.742

10.  CXCL9/10/11, a regulator of PD-L1 expression in gastric cancer.

Authors:  Chenlu Zhang; Zhi Li; Ling Xu; Xiaofang Che; Ti Wen; Yibo Fan; Ce Li; Shuo Wang; Yu Cheng; Xiaoxun Wang; Xiujuan Qu; Yunpeng Liu
Journal:  BMC Cancer       Date:  2018-04-24       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.